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Background: Leptomeningeal metastasis, which results from metastasis of tumors to the arachnoid and pia mater,
can lead to the dissemination of tumor cells throughout the subarachnoid space via the cerebral spinal fluid, and
frequently with a poor prognosis. The primary tumor in adults is most often breast cancer, lung cancer, or
melanoma. Although leptomeningeal metastasis due to cholangiocarcinoma has been reported, to the best of our
knowledge there is no cytologically confirmed report of leptomeningeal metastasis from hepatocellular carcinoma.
Case presentation: We herein report a case of leptomeningeal metastasis from hepatocellular carcinoma in a
53-year-old woman with concomitant systemic metastases to the lung, bone, brain, kidney, adrenal gland,
subcutaneous tissues, and abdominal pelvis. The neurological symptoms of the patient were relieved after
treatment with methotrexate intra-cerebral spinal fluid chemotherapy concurrent with whole brain radiotherapy.
Conclusion: To our knowledge this is the first report of leptomeningeal metastasis from hepatocellular carcinoma
confirmed by cytology. Treatment with methotrexate intra-cerebral spinal fluid chemotherapy concurrent with
whole brain radiotherapy was effective.
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Liver cancer is one of the most common malignancies
and its highest prevalence is in China. The probability of
distant metastasis of liver cancer is 30-50% [1], and the
main metastatic routes are the portal vein, lymphatic
channel, biliary tract, implantation, and the hepatic vein,
among which the last is the most common. Metastatic
foci often form hepatic arteriovenous fistulae via the
hepatic venous system. This enables metastases of the
tumor in the liver and other sites of the body [2]. Un-
common sites of metastases previously reported include
the kidney and adrenal gland, retroperitoneum, pelvic
lymph nodes, diaphragm, skin, brain, pleura, pancreas,
gallbladder, stomach, mouth, bladder, and colon [1-5].
Although leptomeningeal metastasis due to cholangio-
carcinoma has been reported [6], we did not find any* Correspondence: drlhdong@163.com
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metastasis from hepatocellular carcinoma (HCC). Herein
we report a rare case of leptomeningeal metastasis from
HCC and review the relevant literature.Case presentation
A 53-year-old woman was admitted to our hospital due
to fatigue, general malaise, and hiccups for one week.
She had no history of chronic diseases or alcohol or to-
bacco. She had been working at a gas station for more
than seven years.
On examination, painless subcutaneous nodules were
found scattered throughout her body. Routine tests for
hepatic and renal function, and blood and coagulation
were normal, and hepatitis B, hepatitis C, syphilis, and
human immunodeficiency virus tests were all negative.
Tumor marker levels were: CA 125, 1438.0 U/mL; CA
153, 93.63 U/mL; CA 72–4, 300.0 U/mL; NSE, 13.4 ng/mL;. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1.95 ng/mL; and CEA, 155.0 ng/mL.
Computed tomography (CT) of the abdomen showed
multiple lesions in the left lobe of the liver (Figure 1A-D),
bilateral adrenal gland and kidney lesions (Figure 1E), mul-
tiple nodular lesions in the abdominal cavity (Figure 1E),
andmultiple nodules in the subcutaneous fat layer (Figure 1F).
The chest CT scan showed lesions in the inferior lobe of
the right lung and multiple subcutaneous nodular
shadows (Figure 2A). The pelvic CT scan showed pelvic
nodules and multiple subcutaneous nodular shadows
(Figure 2B). The bone scan revealed increased radio-
activity in the right femur (Figure 2C). The patient felt a
headache on the third day of admission and the head
magnetic resonance image showed multiple lesions in
the brain and lesions in the right side of the cerebello-
pontine angle (Figure 2D).
A subcutaneous tumor in the right shoulder was cut
as biopsied, and the pathological examination showed
metastatic cancer invasion (Figure 3A). Immunohisto-
chemical analysis was positive for KI-67 (60%), CK20
(interspersed), CK, villin (focal), Hep Par-1, mammaglo-
bin, CDX2, and TTF1; and negative for vimentin, GPC3,
GCDFP-15, CK5/6, and napsin A. This confirmed the
histological diagnosis of HCC. Histopathological exam-
ination of liver biopsy lesions revealed HCC (middle dif-
ferentiation; Figure 3B). Immunohistochemical analysis
was positive for CK7, CK20 (weak), CK18, CDX2 (weak),
Hep Par-1, TTF1; and negative for GPC3, AFP, and nap-
sin A. Hence, a diagnosis was made of HCC with metas-
tases to the lung, bone, brain, kidney, adrenal gland,
subcutaneous tissues, and abdominal pelvis. The Child-
Pugh grade was A and the Karnofsky performance status
score was 80 points.Figure 1 Abdominal CT. A-D) Plain scanning and triphasic contrast-enhan
kidney lesions. F) Lesions in the subcutaneous fat layer.The patient was treated with a systemic chemotherapy
regimen: oxaliplatin 130 mg on day 1; leucovorin 300 mg
on days 1–2; and tegafur 0.6 g on days 1–2.
The patient felt an aggravated headache three days after
chemotherapy accompanied by hoarseness, dysphagia, and
frequent vomiting, and the Karnofsky performance status
score was 40 points. A lumbar puncture was performed
and the results were: intracranial pressure 370 mm H2O,
protein level 0.54 g/L, sugar level 3.69 mmol/L, and chlor-
ine 96.9 mmol/L. Cytological examination of the cerebral
spinal fluid (CSF) was performed via liquid-based technol-
ogy (ThinPrep TCT2000) and the tumor cells were found
through Papanicolaou staining (Figure 3C). Thus a diag-
nosis of leptomeningeal metastasis was made.
The patient was then given intrathecal chemotherapy
(15 mg methotrexate and 5 mg dexamethasone, once a
week) and concurrent whole brain and skull base
radiotherapy (linear accelerator 6 MV photons, 2 Gy
per day). Two weeks later, the symptoms were relieved
except for dysphagia. However, jaundice appeared and
the size and number of subcutaneous metastatic nod-
ules increased. The liver function tests showed AST, 31
U/L; ALT, 53 U/L; ALP, 99 U/L; GGT, 53 U/L; TBIL,
76.6 μmol/L; DBIL, 33.2 μmol/L; and IBIL, 43.4 μmol/L.
Tumor marker levels were: CA 125 > 5000 U/mL; CA
153 > 300 U/mL; CA 72–4 > 300 U/mL; NSE, 12.1 ng/
mL; CYFRA21-1, 18.6 ng/mL; CA199, 976.4 U/mL;
AFP, 3.28 ng/mL; and CEA, 311.7 ng/mL. Routine blood
tests found hemoglobin 60 g/L and albumin 28.7 g/L.
The Child-Pugh grade was C. After receiving radiotherapy
(30 Gy/15 times) and intra-CSF chemotherapy (4 times),
the patient refused radiotherapy and chemotherapy and
only received supportive treatment. Her swallowing recov-
ered one week later but relapsed after more than 40 days.ced scanning of lesions in the left liver lobe. E) Adrenal gland and
Figure 2 Imaging findings. A) Chest CT showed lesions in the inferior lobe of the right lung. B) Pelvic CT showed pelvic nodules. C) Bone scan
showed increased radioactivity in the right femur. D) MRI scan of the head showed multiple lesions in the brain, with lesions in the right side of
the cerebellopontine angle.
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after diagnosis.Conclusion
Leptomeningeal metastasis is a rare complication in
which metastatic tumor cells invade the leptomeninges
(arachnoid and pia mater) of the meninx and arachnoid
spaces. Leptomeningeal metastasis occurs in approxi-
mately 5% of people with cancer and is usually terminal.Figure 3 Pathology slides of the resected specimen and CSF cytology
B) Biopsy of resected left liver lobe lesions. C) Cytological examination of CIf left untreated, median survival is 4–6 weeks; if
treated, median survival is 2–3 months [7]. Leptomen-
ingeal metastasis is usually secondary to extracranial
solid tumors such as breast cancer, lung cancer, and
melanoma [8-10], while HCC commonly metastasizes
to the lung, regional lymph nodes, peritoneum, adrenal
glands, and brain [11]. To our knowledge, there have
been no previous report in the literature describing
leptomeningeal metastasis secondary to HCC, and this
is the first confirmed by cytological examination.slides. A) Biopsy of subcutaneous tumor in the right shoulder.
SF. Liquid-based technology, pap staining (400×).
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through pathological examination of two lesions (primary
foci and metastases) combined with immunohistochemical
results. Immunohistochemical examination of a subcuta-
neous tumor in the right shoulder tested positive for CK,
Hep Par-1, CDX2, and TTF-1, and negative for vimentin,
and napsin A. The liver biopsy lesions were positive for
CK7, CK18, CDX-2, Hep Par-1, and TTF-1, confirming
the histological diagnosis of HCC.
Most HCCs (70-90%) result from chronic liver disease
and cirrhosis. The risk factors for HCC include virus in-
fection, ingestion of toxin-contaminated food, and alcohol
or autoimmune liver disease [12]. However, the patient in
this report had no history of liver disease but had a long
history of working at a gas station. We therefore speculate
that tumorigenesis may be associated with long-term ex-
posure of petroleum products.
Unlike other cancers that affect the central nervous
system, the clinical signs and symptoms of leptomeningeal
metastasis are highly variable because they affect the entire
neuraxis. The clinical recognition of leptomeningeal me-
tastasis is usually delayed due to ambiguous clinical signs
and symptoms [7]. Although the diagnosis can be difficult,
early diagnosis and leptomeningeal metastasis-related
aggressive treatment can prevent irreversible neurologic
deficits. The most common and definitive method for
leptomeningeal metastasis diagnosis is the demonstra-
tion of malignant cells in the CSF, or spinal magnetic
resonance imaging (MRI). CSF cytological analysis is
the gold standard for identification [7]. In this case,
cytological examination of the CSF was performed via
liquid-based technology and tumor cells were found,
confirming the diagnosis of leptomeningeal metastasis.
Brain metastases from HCC are extremely rare, account-
ing for only 0.2-2.2% of all metastases [5], but 40-70% of
brain metastases can cause cerebral hemorrhage and are
often associated with a poor prognosis. Previously re-
ported brain metastases from HCC have complicated
symptoms such as cranial nerve palsy, but a clear diagno-
sis of leptomeningeal metastasis using a CSF test was not
performed [5,13,14]. The brain metastases in this patient
were small and had no significant effect due to mass. In
addition, we found lesions in the right side of the cere-
bellopontine angle, indicating cranial nerve injury. This
case had no specific imaging of leptomeningeal metasta-
sis such as thickness of the leptomeninx, but imaging
was characteristic, including brain ventricle metastases
and metastatic nodules near the pallium, which can as-
sist the diagnosis. Furthermore, the patient had severe
and diverse symptoms associated with the central ner-
vous system, indicating leptomeningeal metastasis.
Leptomeningeal metastasis can be caused by hema-
togenous spread or invasion of brain metastases. If the
metastatic lesions in the lateral cerebral ventricle lesioninvade into the lateral ventricle ependymal, or the le-
sions in the right cerebral peduncle invade into the pia
mater of the cisterna ambiens, the tumor cells may shed
into the subarachnoid space and proliferate in the CSF,
inducing leptomeningeal metastasis [7].
Leptomeningeal metastasis is a fatal complication of
malignancies and difficult to treat; the median overall
survival of treated patients is only 2 to 3months [15]. The
goal of leptomeningeal metastasis-directed treatment is to
stabilize the neurological status, improve quality of life,
and prolong survival. Systemic and intra-CSF chemother-
apy and site-specific radiotherapy are common treatment
approaches [16]. In this report, the patient received con-
current radiotherapy and chemotherapy and achieved
good effect without severe side effects. This may be be-
cause methotrexate is an antimetabolite drug and is cell
cycle-specific, acting mainly on S phase. Since tumor cells
in the S stage are resistant to radiotherapy, a combination
of chemotherapy and radiotherapy can enhance the an-
titumor effect. Furthermore, methotrexate has a radio-
sensitizing effect [17].
A randomized, multicenter, open-label study found that
oxaliplatin plus a fluorouracil/leucovorin regimen had ob-
vious benefits for treating advanced HCC with distant me-
tastasis [18]. However, the patient in the present report
was administered this regimen and incurred jaundice two
weeks after the chemotherapy, consistent with hepato-
cellular jaundice, and the subcutaneous metastatic le-
sion significantly progressed with signs of anemia and
hypoalbuminemia, indicating the tumor was uncontrolled.
In 30-40% of Chinese patients with HCC, alpha-
fetoprotein is normal. Patients with high levels of alpha-
fetoprotein frequently have a high grade of malignancy
and poor prognosis [19]. For the patient of the present
case, several tumor markers were significantly elevated
but alpha-fetoprotein was normal. Imaging modalities
indicated that liver malignancies comprised multiple
nodular lesions, not typical of liver cancer.
This is a rare case in that the clinical features, biological
behavior of the tumor, and response to treatment were
quite different from most HCCs.
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